Taysha Gene Therapies, Inc.
TSHA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $1,986 | $2,302 | $2,022 |
| % Growth | -100% | -13.7% | 13.8% | – |
| Cost of Goods Sold | $286 | $0 | $0 | $0 |
| Gross Profit | -$286 | $1,986 | $2,302 | $2,022 |
| % Margin | – | 100% | 100% | 100% |
| R&D Expenses | $25,459 | $20,141 | $15,565 | $15,325 |
| G&A Expenses | $8,279 | $8,598 | $8,158 | $6,629 |
| SG&A Expenses | $8,279 | $8,598 | $8,158 | $6,629 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $33,738 | $28,739 | $23,723 | $21,954 |
| Operating Income | -$34,024 | -$26,753 | -$21,421 | -$19,932 |
| % Margin | – | -1,347.1% | -930.5% | -985.8% |
| Other Income/Exp. Net | $1,291 | -$129 | -$108 | $1,147 |
| Pre-Tax Income | -$32,733 | -$26,882 | -$21,529 | -$18,785 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$32,733 | -$26,882 | -$21,529 | -$18,785 |
| % Margin | – | -1,353.6% | -935.2% | -929% |
| EPS | -0.093 | -0.09 | -0.08 | -0.092 |
| % Growth | -2.7% | -12.9% | 12.9% | – |
| EPS Diluted | -0.093 | -0.09 | -0.08 | -0.092 |
| Weighted Avg Shares Out | 353,310 | 297,989 | 269,306 | 204,943 |
| Weighted Avg Shares Out Dil | 353,310 | 297,989 | 269,306 | 204,943 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,169 | $1,859 | $1,326 | $1,700 |
| Interest Expense | $15 | $17 | $19 | $22 |
| Depreciation & Amortization | $286 | $277 | $283 | $304 |
| EBITDA | -$32,432 | -$26,588 | -$21,227 | -$18,459 |
| % Margin | – | -1,338.8% | -922.1% | -912.9% |